Travere Therapeutics (NASDAQ:TVTX) Price Target Lowered to $10.00 at Piper Sandler

Travere Therapeutics (NASDAQ:TVTX – Free Report) had its price target lowered by Piper Sandler from $19.00 to $10.00 in a research note released on Wednesday, Benzinga reports. The firm currently has a neutral rating on the stock. TVTX has been the subject of several other research reports. JPMorgan Chase & Co. started coverage on Travere […]

Related Keywords

United States ,America ,Peter Heerma ,Ericm Dube ,Piper Sandler ,Jpmorgan Chase Co ,Russell Investments Group Ltd ,Group Plc ,Envestnet Asset Management Inc ,Travere Therapeutics Inc ,Travere Therapeutics Company Profile ,Alphacentric Advisors ,Barclays ,Huntington National Bank ,Travere Therapeutics ,Free Report ,Moderate Buy ,Therapeutics Stock Down ,Get Free Report ,National Bank ,Asset Management ,Investments Group ,General Group Plc ,Centric Advisors ,Travere Therapeutics Daily ,Nasdaq Tvtx ,Tvtx ,Medical ,Lower Price Target ,